Takeda Pharmaceutical (TAK) Cash from Operations (2018 - 2026)

Takeda Pharmaceutical's Cash from Operations history runs 9 years deep, the most recent figure standing at 475231517.53 for Q1 2026.

• In Q1 2026, Cash from Operations fell 67.36% year-over-year to 475231517.53; the TTM figure through Mar 2026 stood at 6956339437.92 (changed 0.02% YoY), while the FY2026 annual figure was 6918418458.19, changed 0.31% from the prior year.
• Cash from Operations was 475231517.53 for Q1 2026 at Takeda Pharmaceutical, down from 2425354411.72 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 3626205754.83 in Q1 2023 to a low of 475231517.53 in Q1 2026.
• Historically, Cash from Operations has averaged 1881568313.6 across 5 years, with a median of 1600108410.1 in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash from Operations surged 154.78% in 2024, then tumbled 67.36% in 2026.
• A 5-year view of Cash from Operations shows it stood at 2677225361.33 in 2022, then slumped by 62.99% to 990775096.48 in 2023, then jumped by 154.78% to 2524260483.73 in 2024, then dropped by 3.92% to 2425354411.72 in 2025, then tumbled by 80.41% to 475231517.53 in 2026.
• The last three Cash from Operations figures came in at 475231517.53 (Q1 2026), 2425354411.72 (Q4 2025), and 2566942324.35 (Q3 2025), per Business Quant data.